Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Turcot syndrome 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Ascites 1

Interventions

pembrolizumab 5Nivolumab 5Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1sintilimab 1regorafenib 1fludarabine phosphate 1fludarabine 1danvatirsen 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Interleukin-2 1Immunoglobulin G 1IMM-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × danvatirsen × Gastrointestinal × Clear all
NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡